Contrasting Immunovant (NASDAQ:IMVT) & Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics (NASDAQ:JSPR) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations for Jasper Therapeutics and Immunovant, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jasper Therapeutics	0	0	10	0	3.00
Immunovant	0	0	10	0	3.00

Jasper Therapeutics currently has a consensus target price of $73.38, indicating a potential upside of 256.19%. Immunovant has a consensus target price of $47.89, indicating a potential upside of 82.23%. Given Jasper Therapeutics’ higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Immunovant.

Profitability

This table compares Jasper Therapeutics and Immunovant’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jasper Therapeutics	N/A	-67.64%	-58.53%
Immunovant	N/A	-56.40%	-52.03%

Valuation and Earnings

This table compares Jasper Therapeutics and Immunovant”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jasper Therapeutics	N/A	N/A	-$64.46 million	($4.74)	-4.35
Immunovant	N/A	N/A	-$259.34 million	($2.22)	-11.84

Immunovant is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Jasper Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.

Institutional & Insider Ownership

79.8% of Jasper Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 2.7% of Jasper Therapeutics shares are held by company insiders. Comparatively, 5.9% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Jasper Therapeutics beats Immunovant on 5 of the 9 factors compared between the two stocks.

About Jasper Therapeutics

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

About Immunovant

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.